Solid Cancers After Bone Marrow Transplantation

Bhatia, Smita; Louie, Andrew D.; Bhatia, Ravi; O’Donnell, Margaret; Fung, Henry C.; Kashyap, Ashwin; Krishnan, Amrita; Molina, Arturo; Nademanee, Auayporn; Niland, Joyce C.; Parker, Pablo; Snyder, David S.; Spielberger, Ricardo; Stein, Anthony S.; Forman, Stephen J.

doi:10.1200/jco.2001.19.2.464

Cited by 290 publications

(243 citation statements)

References 26 publications

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…Because these practices are relatively new, their impact on risk for SN is poorly understood. Most studies have shown no association, 22,36,38,41 but they are generally small with limited follow-up.…”

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

“…62 In contrast, two other studies found no association between pre-HCT chemotherapy and risk of SN. 41,62 Pre-HCT radiotherapy has been shown to be an adverse risk factor for SN. 59,60,62 Among 133 patients with aplastic anemia undergoing allogeneic HCT, pre-HCT immunosuppressive therapy with cyclosporine (a group 1 carcinogen according to the International Agency for Research on Cancer) 124 was associated with five-fold higher rates of SN.…”

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

“…39,125 However, the role of TBI in SN risk remains unresolved, with six publications providing strong evidence of increased SN risk from TBI exposure, 16,17,32,46,49,60 and eight studies failing to identify an association between TBI and SN. 22,24,33,37,38,41,59,69 …”

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

See 2 more Smart Citations

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

Morton

Saber

Baker

et al. 2017

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

Subsequent neoplasms (SN) following hematopoietic cell transplantation (HCT) cause significant patient morbidity and mortality. Risks for specific SN types vary substantially, with particularly elevated risks for post-transplant lymphoproliferative disorders, myelodysplastic syndrome/acute myeloid leukemia, and squamous cell malignancies. This consensus document provides an overview of the current state of knowledge regarding SN after HCT and recommends priorities and approaches to overcome challenges and gaps in understanding. Numerous factors have been suggested to impact risk, including patient-related (e.g., age), primary disease-related (e.g., disease type, pre-HCT therapies), and HCT-related characteristics (e.g., type and intensity of conditioning regimen, stem cell source, development of graft-versus-host disease). However, gaps in understanding remain for each of these risk factors, particularly for patients receiving HCT in the current era due to substantial advances in clinical transplantation practices. Additionally, the influence of non-transplant-related risk factors (e.g., germline genetic susceptibility, oncogenic viruses, lifestyle factors) is poorly understood. Clarification of the magnitude of SN risks and identification of etiologic factors will require large-scale, long-term, systematic follow-up of HCT survivors with detailed clinical data. Most investigations of the mechanisms of SN pathogenesis after HCT have focused on immune drivers. Expansion of our understanding in this area will require interdisciplinary laboratory collaborations utilizing measures of immune function and availability of archival tissue from SN diagnoses. Consensus-based recommendations for optimal preventative, screening, and therapeutic approaches have been developed for certain SN after HCT, whereas for other SN, general population guidelines are recommended. Further evidence is needed to specifically tailor preventative, screening, and therapeutic guidelines for SN after HCT, particularly for unique patient populations. Accomplishment of this broad research agenda will require increased investment in systematic data collection with engagement from patients, clinicians, and interdisciplinary scientists in order to reduce the burden of SN in the rapidly growing population of HCT survivors.

show abstract

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

Section: Disease- and Transplant-related Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

Morton

Saber

Baker

et al. 2017

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

show abstract

“…A predilection to prostate malignancy was reported by multiple authors. Whereas, of the six secondary malignancies amongst 392 CML patients reported by Bhatia et al [19], none affected prostate (all had either cervical or oral cancers). Study from animal models have shown increased frequency of malignancies of parathyroid, stomach, adrenal, renal and urinary system in rats who received imatinib of 60 mg/kg/day [20].…”

Section: Secondary Malignancies In Cml: Pre-imatinib Eramentioning

confidence: 84%

“…Authors have reported secondary malignancies with predilection to specific organs/body sites, particularly head/neck, cervical and prostate [15,19,23]. This site predilection would be influenced by various other factors including regional prevalence, eating habits, smoking behaviour, physician reporting etc.…”

Section: Secondary Malignancies In Tki Treated CMLmentioning

confidence: 99%

CML as Part of Dual Malignancies—A Retrospective Analysis: Possible Mechanisms and Review of Literature

Sahu

Yanamandra

Bal

et al. 2015

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Introduction of imatinib has changed the outlook of chronic myeloid leukaemia (CML) patients with overall survival approaching general population. Long term survival in CML patients has provided an opportunity to better study natural history and long term complications of disease as well as the treatment modalities. To study the occurrence and association of other malignancies with their outcomes in patients with CML. This is a single centre retrospective study. All CML patients case records registered with haematology clinic of a tertiary care centre in North India from 2001 to 2014 were perused and evaluated for dual malignancies. Those patients with dual malignancies were personally examined and interviewed if alive. Out of 1677 patients, 15 cases had co-existent malignancies. Four of fifteen cases of dual malignancies had CML as secondary cancer. Three had synchronous and rest 12 patients had metachronous malignancies. Only one patient was in accelerated phase, rest all were in chronic phase. Median age of the dual malignancy cases was 50 years (25-66 years), much younger than reported in west. The initial dose of imatinib was 400 mg OD in all except one.We did not find any causal association between CML or imatinib therapy with development of secondary tumours. Interestingly in this series, incidence of CML as secondary or synchronous malignancy was higher than earlier published studies.

show abstract

Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients

et al. 2015

View full text Add to dashboard Cite

show abstract

Solid Cancers After Bone Marrow Transplantation

Abstract: The risk of radiation-associated solid tumor development after BMT is likely to increase with longer follow-up. This underscores the importance of close monitoring of patients who undergo BMT.

Cited by 290 publications

References 26 publications

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report

CML as Part of Dual Malignancies—A Retrospective Analysis: Possible Mechanisms and Review of Literature

Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients

Contact Info

Product

Resources

About